Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: DM Clear all
Completed No phase listed Observational

Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging

NCT03052166
View directory record Official record
Conditions
Breast
Interventions
QT Ultrasound scan
Device
Lead sponsor
QT Ultrasound LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
755 participants
Timeline
2017 – 2020
U.S. locations
2
States / cities
Long Beach, California • Novato, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

NCT03095066
View directory record Official record
Conditions
Neurobehavioral Disinhibition
Interventions
Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
54
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Mulberry Leaf on Type 2 Diabetes

NCT00795704
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mulberry Leaf Extract, Placebo
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

NCT03795389
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
Interventions
DM199
Drug
Lead sponsor
DiaMedica Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Not applicable Interventional

The Effect of 3 Different Models of MNT on DM Control in Overweight Patients With T2DM

NCT02520050
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Traditional MNT, Structured MNT, Structured MNT plus Weekly Support
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
30 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 3:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

NCT04999020
View directory record Official record
Conditions
Dermatomyositis
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Irvine, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jun 10, 2026, 3:32 AM EDT
Recruiting Not applicable Interventional

NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study

NCT06593327
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Interventions
Intensive Prevention Strategy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus

NCT00850096
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo for Nasulin, Nasulin
Other · Drug
Lead sponsor
CPEX Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Chandler, Arizona • Escondido, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Not applicable Interventional

Evaluation of the Impact of a Food is Medicine Program on Diabetes-related Health Outcomes for People With Type 2 Diabetes in a Low Income Community-based Setting Compared to Usual Care

NCT07529184
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Food is medicine
Dietary Supplement
Lead sponsor
Public Health Institute Center for Wellness and Nutrition
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Not applicable Interventional

The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes

NCT01648244
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
Computer-Assisted Decision Support
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Jun 10, 2026, 3:32 AM EDT
Recruiting Not applicable Interventional

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

NCT06906640
View directory record Official record
Conditions
Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
Interventions
(IRIS-CKD Management Program): Education, (IRIS-CKD Management Program): GDMT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 10, 2026, 3:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 10, 2026, 3:32 AM EDT
Terminated Not applicable Interventional

Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

NCT00743756
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
home-delivered meals, diabetes education for 12 months
Dietary Supplement · Behavioral
Lead sponsor
Emory University
Other
Eligibility
65 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Jun 10, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

NCT04044690
View directory record Official record
Conditions
Dermatomyositis
Interventions
human immunoglobulin G, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
15
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients

NCT05583877
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes BOOST, Usual Care
Behavioral
Lead sponsor
Daniel Amante
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02442765
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
111
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jun 10, 2026, 3:32 AM EDT
Withdrawn Early Phase 1 Interventional

Glucagon-like Peptide-1 in Type 1 Diabetes

NCT04355832
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Glucagon-like peptide-1, Placebos
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 10, 2026, 3:32 AM EDT
Completed Not applicable Interventional

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3

NCT00742521
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glucose clamp
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Jun 10, 2026, 3:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes Mellitus Effect on Bone Mineral Density

NCT01633684
View directory record Official record
Conditions
Diabetes Mellitus, Osteoporosis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jun 10, 2026, 3:32 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Empowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City

NCT07556354
View directory record Official record
Conditions
Blood Cholesterol, Blood Pressure Monitoring, Weight Change, BMI, Diabetes Education, Diabetes (DM)
Interventions
Remote Patient Monitoring in a Faith-Based Program, Traditional Cohort Faith-based DSMES program
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 10, 2026, 3:32 AM EDT
Recruiting Phase 3 Interventional

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786
View directory record Official record
Conditions
Myositis
Interventions
PF-06823859, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
47
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 3:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Finding Diabetes Mellitus Among Veterans

NCT00007696
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
45 Years to 64 Years
Enrollment
1,276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Jun 10, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

NCT07111065
View directory record Official record
Conditions
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions
FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
Dietary Supplement
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 10, 2026, 3:32 AM EDT